he 2024 Muscular Dystrophy Association (MDA) Summit convened researchers, clinicians, patient advocates, and regulatory experts to address the rapidly evolving gene therapy landscape for neuromuscular disorders. With increasing momentum behind AAV-based therapeutic programs, the summit focused on ensuring that innovation is paired with robust safety monitoring and equitable patient access.

Speakers from the NIH, leading academic centers, and clinical gene therapy programs emphasized critical considerations such as:

     Immune responses to AAV vectors and strategies to mitigate risk

     Scalable manufacturing to support broader distribution

     Long-term patient monitoring and registry development

     Ethical considerations for pediatric and first-in-human trials

     Readiness of treatment centers for genetic medicine administration

One of the landmark announcements was the formation of the MDA Gene Therapy Support Network, designed to prepare clinical sites with standardized protocols, safety practices, and patient-care infrastructure.

These discussions are highly relevant to emerging programs targeting ultra-rare neuromuscular conditions — including CHKB-associated muscular dystrophy — where careful vector selection, tissue targeting, and monitoring strategies are essential.

The summit underscores a unified commitment to ensuring gene therapy advances responsibly, effectively, and inclusively.

Discover how HaliGene is contributing to the next generation of safe and precise neuromuscular gene therapies.